Can Novo Nordisk Make a Comeback? New Weight-Loss Pill Approval Ignites a High-Stakes 2026 Showdown
Key Points Novo Nordisk’s fall from Wall Street favorite to major laggard has set the tone for a tense 2026, as the weight-loss drug powerhouse scrambles to rebuild investor trust and stabilize its blockbuster business. After suffering its worst stock performance in company history, Novo faced a long list of setbacks: multiple guidance cuts, rapid … Read more